Intelligence / Healthtech / New Clinical Trials / Lumosa Therapeutics Co., Ltd.
Clinicaltrial registered22 Oct 2026
Lumosa Therapeutics Co., Ltd.
22 Oct 2026: Trial registered · A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 22 Oct 2026
- Title
- A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant
- Conditions
- Acute Ischemic Stroke
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- Taiwan
- Country
- Taiwan
- Reference
- NCT07890298
- Location
- Taiwan
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Lumosa Therapeutics Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Taiwan
New Clinical Trials
12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothClinical4 NovBoehringer Ingelheimtrial registered · A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Clinical3 NovArjil Pharmaceuticals LLCtrial registered · A Study for AR100DP1 in Mild to Moderate Atopic DermatitisClinical29 OctElixiron Immunotherapeutics Inc.trial registered · A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy VolunteersClinical27 OctT-MAXIMUM Pharmaceutical Inctrial registered · The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid TumorsClinical22 OctBionime Corporationtrial registered · RIGHTEST iFree 2 CGM System for Glycemic Control in Adults With Diabetes MellitusClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.